^
Association details:
| Biomarker: | MDM2 overexpression |
|---|---|
| Cancer: | Liposarcoma |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) + idasanutlin (RG7388) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Analysis of the role of FGFR signaling in liposarcomas: Dual targeting of FGFR and MDM2 is synergistic
Excerpt:
MDM2 overexpression being the hallmark of WD/DDLPS, we investigated the effects of the MDM2-TP53 interaction inhibitor RG7388 (idasanutlin) in combination with erdafitinib . Interestingly, we found that the combination of RG7388 and erdafitinib exerts a highly synergistic effect on both viability and apoptosis in all our WDLPS and DDLPS cell lines.
